STOCK TITAN

Personalis (PSNL) Stock News, Sep-Oct 2020

PSNL NASDAQ

Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.

News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in upcoming investor conferences. The company will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 4:15 p.m. ET. Additionally, it will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020. Personalis focuses on providing comprehensive molecular data through its ImmunoID NeXT Platform, aimed at enhancing cancer therapy development. The firm is also involved in the VA Million Veterans Program to sequence veteran genomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
conferences
-
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will release its Q3 2020 financial results on November 5, 2020, post-market. A conference call and webcast will be held at 2:00 PM PT / 5:00 PM ET to discuss these results and recent developments. The company specializes in advanced genomic solutions for cancer, utilizing its ImmunoID NeXT Platform to analyze 20,000 human genes and immune responses from patient samples. Personalis is also partnering with the VA Million Veterans Program to sequence over two million veteran genomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
-
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) announced its participation at the Immuno Series US Virtual meeting on October 15-16, 2020. The company will present on maximizing biomarker discovery using its ImmunoID NeXT™ platform. Dr. Kedar Hastak will address challenges in immuno-oncology research and how enhanced biomarker analysis can inform combinatorial immunotherapy. The platform integrates DNA and RNA sequencing for a comprehensive cancer characterization, showcasing case studies that reveal insights into tumor biology and treatment efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) announced its participation in the online conference IO Combinations 360˚ on October 1-2, 2020. Dr. Travis Yates will present on the "Comprehensive immunogenomics to enable composite biomarkers for immunotherapy response using a sample sparing approach." The presentation will cover the innovative ImmunoID NeXT platform, focusing on its benefits in immuno-oncology research, including case studies from metastatic melanoma patients. Personalis aims to enhance cancer therapy development by providing detailed genomic data about patients’ cancers and immune responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
conferences
-
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) announces its participation in the Digital World CB & CDx meeting from September 29 to October 1, 2020. The company will present on the ImmunoID NeXT™ platform, addressing challenges in immuno-oncology research. Dr. Kedar Hastak will highlight the platform’s ability to consolidate biomarker assays for a comprehensive view of tumor-immune interactions. Additionally, Personalis is advancing precision medicine with its NeXT Dx™ and NeXT CDx™ diagnostic initiatives. The company focuses on delivering extensive molecular data to support cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
conferences

FAQ

What is the current stock price of Personalis (PSNL)?

Personalis (PSNL) last closed at $15.71.

What is the market cap of Personalis (PSNL)?

The market cap of Personalis (PSNL) is approximately $1.7B.